Literature DB >> 24043639

The Plexin-B family and its role in cancer progression.

Muhammad Faraz Arshad Malik1, Lin Ye1, Wen G Jiang2.   

Abstract

Plexins are transmembrane protein receptors for semaphorin molecules. These molecules are involved in numerous cellular activities related to cell proliferation, adhesion along with the basement membrane, cellular motility and invasive capability. All nine members of Plexins identified in vertebrates have been grouped into subclasses, termed Plexin-A, Plexin-B, Plexin-C and Plexin-D. Plexin-B consists of three members, namely Plexin-B1, Plexin-B2 and Plexin-B3. Plexin-B1 functionally interacts with Sema4A (Yukawa et al., 2010) and can also form heterodimer with Plexin-B2 for Sema4A binding (Nkyimbeng-Takwi et al., 2011). Plexin-B2 binds with Sema4C. Plexin-B3 mediates interaction with both Sema4G and Sema5A. Some semaphorines exist in a membrane-bound form only, whereas other family members can be found in tissues/fluids in both secreted and membrane-bound forms. This ligand-receptor interaction between sema4D and Plexin-B1 indicated in different signaling pathways results in many intriguing and interesting findings, highlighting its importance in both physiology and pathology. Apart from bidirectional signaling among these molecules, the involvement of Plexin-B1 in the processes described here directly involves a bidirectional singaling between Sema4Dand Plexin-B1. Being a high affinity receptor for both Sema4A and Sema4D, the role played by Plexin-B1 in cancer progression, metastasis and angiogenesis is still an area requiring further research. Activation of Sema4D mediated downstream effectors is largely influenced by cross talk of Plexin-B1 with other molecules, such as Her-2 and Met. In this review, all findings regarding Plexin-B1 upstream and downstream regulation and its putative involvement in relation to the ultimate fate of cancer cells are discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24043639     DOI: 10.14670/HH-29.151

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  10 in total

Review 1.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

Review 2.  Semaphorins 4A and 4D in chronic inflammatory diseases.

Authors:  Svetlana P Chapoval; Zahava Vadasz; Andrei I Chapoval; Elias Toubi
Journal:  Inflamm Res       Date:  2016-08-23       Impact factor: 4.575

3.  Identification of a circRNA-mediated comprehensive ceRNA network in spinal cord injury pathogenesis.

Authors:  Chao Zu; Jingyuan Li; Xijing He; Le Ji; Xia Li
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-11

4.  Plexin-B2 and Semaphorins Do Not Drive Rhabdomyosarcoma Proliferation or Migration.

Authors:  Anju Karki; Reshma Purohit; Sofia Nosack; Narendra Bharathy; Joel E Michalek; Sonja Chen; Charles Keller
Journal:  Sarcoma       Date:  2022-05-06

5.  Intact CD100-CD72 Interaction Necessary for TCR-Induced T Cell Proliferation.

Authors:  Xiaojun Jiang; Niklas K Björkström; Espen Melum
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

Review 6.  Semaphorins as Potential Immune Therapeutic Targets for Cancer.

Authors:  Jun Jiang; Fang Zhang; Yi Wan; Ke Fang; Ze-Dong Yan; Xin-Ling Ren; Rui Zhang
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

7.  A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.

Authors:  Maureen Elizabeth Trudeau; Judith-Anne W Chapman; Baoqing Guo; Mark J Clemons; Rebecca A Dent; Roberta A Jong; Harriette J Kahn; Kathleen I Pritchard; Lei Han; Patti O'Brien; Lois E Shepherd; Amadeo M Parissenti
Journal:  Springerplus       Date:  2015-10-21

Review 8.  Semaphorin 3C and Its Receptors in Cancer and Cancer Stem-Like Cells.

Authors:  Jing Hao; Jennifer S Yu
Journal:  Biomedicines       Date:  2018-04-08

Review 9.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

10.  Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.

Authors:  Sharon E Johnatty; Jonathan P Tyrer; Siddhartha Kar; Jonathan Beesley; Yi Lu; Bo Gao; Peter A Fasching; Alexander Hein; Arif B Ekici; Matthias W Beckmann; Diether Lambrechts; Els Van Nieuwenhuysen; Ignace Vergote; Sandrina Lambrechts; Mary Anne Rossing; Jennifer A Doherty; Jenny Chang-Claude; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Douglas A Levine; Lambertus A Kiemeney; Leon F A G Massuger; Jacek Gronwald; Jan Lubiński; Anna Jakubowska; Cezary Cybulski; Louise Brinton; Jolanta Lissowska; Nicolas Wentzensen; Honglin Song; Valerie Rhenius; Ian Campbell; Diana Eccles; Weiva Sieh; Alice S Whittemore; Valerie McGuire; Joseph H Rothstein; Rebecca Sutphen; Hoda Anton-Culver; Argyrios Ziogas; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Celeste L Pearce; Malcolm C Pike; Daniel O Stram; Anna H Wu; Jolanta Kupryjanczyk; Agnieszka Dansonka-Mieszkowska; Iwona K Rzepecka; Beata Spiewankiewicz; Marc T Goodman; Lynne R Wilkens; Michael E Carney; Pamela J Thompson; Florian Heitz; Andreas du Bois; Ira Schwaab; Philipp Harter; Jacobus Pisterer; Peter Hillemanns; Beth Y Karlan; Christine Walsh; Jenny Lester; Sandra Orsulic; Stacey J Winham; Madalene Earp; Melissa C Larson; Zachary C Fogarty; Estrid Høgdall; Allan Jensen; Susanne Kruger Kjaer; Brooke L Fridley; Julie M Cunningham; Robert A Vierkant; Joellen M Schildkraut; Edwin S Iversen; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Irene Orlow; Tanja Pejovic; Yukie Bean; Claus Høgdall; Lene Lundvall; Ian McNeish; James Paul; Karen Carty; Nadeem Siddiqui; Rosalind Glasspool; Thomas Sellers; Catherine Kennedy; Yoke-Eng Chiew; Andrew Berchuck; Stuart MacGregor; Paul D P Pharoah; Ellen L Goode; Anna deFazio; Penelope M Webb; Georgia Chenevix-Trench
Journal:  Clin Cancer Res       Date:  2015-07-07       Impact factor: 12.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.